Iron deficiency

Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants

Retrieved on: 
Tuesday, September 19, 2023
Health, Infectious Diseases, Genetics, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Vaccine, Infection, European Scientific Cooperative on Phytotherapy, Diversified Specialty Institute Holdings, Inc., Influenza, Omicron, AE, Vaccination, SARS-CoV-2, Nephrology, SARS-CoV-2 Omicron variant, Public, Aes, Hereditary angioedema, Drug, Haemophilia, ARCT, CSL, Cell, RNA, Delta, Messenger, HAE, Iron deficiency, Patient, Beta, Liver, Poster, Immunodeficiency, Conference, North West Ambulance Service, B.1, Arcturus

Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.

Key Points: 
  • Three sa-mRNA vaccines were used in the study, which was presented as a poster at the European Scientific Working Group on Influenza's 9th ESWI Influenza Conference in Valencia, Spain.
  • However, sa-mRNA also provides the body with instruction to make copies of the mRNA, amplifying the amount of protein made.
  • This advanced technology has shown the potential to offer longer duration of immune response at considerably lower doses compared to conventional mRNA vaccines.
  • Similar trends were observed for other SARS-CoV-2 variants including Beta, Delta, Omicron BA.1, Omicron BA.2, and Omicron BA.4/5.

Future diets will be short of micronutrients like iron — it’s time to consider how we feed people

Retrieved on: 
Friday, September 1, 2023
Shift, Fortification, Adoption, Pregnancy, Food, Mineral, Diet, Nut, Drink, Awareness, FSANZ, Seed, Poultry, Anemia, Red meat, Heme, Nutrient, Woman, Hope, Grain boundary strengthening, Vegetable, COVID, Government, Vitamin, Nutrient deficiency, Iron deficiency, Folate, Risk, Tea, Coffee, Food Standards Australia New Zealand, Ageing, Health, Meat, Bread, Dietary supplement, Salt, Central Africa, Iron

In New Zealand, 10.6% of women aged 15-18 and 12.1% of women aged 31-50 suffer from iron deficiency.

Key Points: 
  • In New Zealand, 10.6% of women aged 15-18 and 12.1% of women aged 31-50 suffer from iron deficiency.
  • As more people consider switching to plant-based diets, the risk of iron deficiency will likely increase.
  • We argue that fortifying foods with iron could provide a one-stop solution to bridge nutrient gaps caused by inadequate dietary intake.

Food fortification

    • Many foods in supermarket shelves, including common staples such as bread and cereals, already have added nutrients.
    • Unlike mandatory iodine and folic acid fortification of bread, there is currently no government initiative to encourage or mandate iron fortification in New Zealand.

Shift to plant-based diets

    • More consumers are opting for diets that include fewer animal-sourced foods in the hope of reducing environmental impacts and emissions.
    • Recent statistics show a 19% increase in the adoption of vegan and vegetarian diets among New Zealanders from 2018 to 2021.
    • Considering these plant-based diets for a sustainable food system must involve conversations about nutrient availability.
    • Read more:
      What to drink with dinner to get the most iron from your food (and what to avoid)

      Fortification can be a potent strategy in helping people to shift towards plant-based diets by enriching these diets with nutrients that would otherwise be lacking.

Is NZ ready for iron-fortified foods?

    • Given the importance of adequate dietary iron intake and the projected shortage in dietary iron, it is crucial to evaluate the benefits of fortification.
    • Educational interventions such as promoting awareness of iron deficiency and positive impacts of fortification may help improve consumers’ acceptance of these initiatives.
    • Mahya Tavan receives funding from the Global Dairy Platform for developing a dietary optimisation model called The iOTA Model.

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

Retrieved on: 
Monday, August 28, 2023
IV, Heart failure, Hospital, University of Medicine 1, Yangon, Class, The New England Journal of Medicine, HF, Quality of life, European Society of Cardiology, CSL Vifor, Cardiology, Iron deficiency, Patient, Physician, Risk, Heart, Diagnosis, ESC, Dietary supplement, Medical device

ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®.

Key Points: 
  • The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF.
  • ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®.
  • We are particularly pleased with the updated recommendations for IV iron including Ferinject® in the new 2023 focused update of the 2021 treatment guidelines.
  • This revision will enable cardiologists and physicians to better treat more of the symptomatic heart failure patients with iron deficiency."

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

Retrieved on: 
Monday, August 28, 2023
IV, Heart failure, Hospital, University of Medicine 1, Yangon, Class, The New England Journal of Medicine, HF, Quality of life, European Society of Cardiology, CSL Vifor, Cardiology, Iron deficiency, Patient, Physician, Risk, Heart, Diagnosis, ESC, Dietary supplement, Medical device

ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®.

Key Points: 
  • The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF.
  • ST. GALLEN, Switzerland, Aug. 28, 2023 /PRNewswire/ -- CSL Vifor is pleased to announce that the European Society of Cardiology (ESC) have upgraded recommendations in the ESC 2023 guidelines for the treatment of iron deficiency acute and chronic HF with IV iron supplementation, including Ferinject®.
  • We are particularly pleased with the updated recommendations for IV iron including Ferinject® in the new 2023 focused update of the 2021 treatment guidelines.
  • This revision will enable cardiologists and physicians to better treat more of the symptomatic heart failure patients with iron deficiency."

American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®

Retrieved on: 
Saturday, August 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Exercise, Conditional sentence, Regent, The New England Journal of Medicine, IV, Heart failure, University of Medicine 1, Yangon, Hospital, Hotline, Duke University School of Medicine, Associate, Parallel Walk Test, New York Heart Association Functional Classification, Death, Iron deficiency, Patient, Iron, Heart, European Society of Cardiology, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Medical imaging, Pharmaceutical industry, MD

American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF).

Key Points: 
  • American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF).
  • While there was a numerical improvement in the hierarchical composite endpoint, the trial did not meet statistical significance on the primary endpoint, which was a hierarchical composite of death and heart failure hospitalization at 12 months and change from baseline to 6 months in the 6-minute walk test distance.1 The HEART-FID trial was designed as a single pivotal study instead of two based upon a special protocol assessment with the U.S. Food and Drug Administration (FDA).
  • As a result, the study included a significance level for the final analysis of 0.0099 for the primary endpoint preserving the overall significance at 0.01.1 The safety profile of ferric carboxymaltose injection was consistent with previous reports with no new safety concerns identified.1
    Data from the HEART-FID study (NCT03037931) were presented today in a late-breaking research Hot Line session at the European Society of Cardiology Congress 2023.
  • Although there was a numerical improvement in the hierarchical composite endpoint, the study did not meet the pre-specified significance level of 0.0099.1
    “This trial addresses important clinical questions of diagnosing and treating iron deficiency in patients with heart failure at a specified dose regimen of ferric carboxymaltose to reduce rates of death and hospitalization as well as improve function,” said Robert Mentz, MD, Associate Professor in the Department of Medicine at Duke University School of Medicine , and Member of the Duke Clinical Research Institute and Clinical Lead for the trial.

NIH Awards Amulet SBIR Grant for Consumer Gluten Sensor

Retrieved on: 
Monday, August 7, 2023
Food, Fatigue, Amulet, SBIR, Myalgia, Small Business Innovation Research, Food safety, Triticale, Human, Ataxia, Constipation, Brain, Dartmouth College, Gluten-related disorders, Foundation for the National Institutes of Health, Asthma, Plant, Chemistry, Pesticide, Wheat allergy, Iron deficiency, Patient, Dermatitis herpetiformis, Restaurant, Joint, Bloating, Immunology, Health, FDA, NIH, Skin, Migraine, Flour, Pharmaceutical industry

MADISON, Wis., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Amulet, maker of the world's smallest, fastest, and portable electrochemical food sensor, announced today the receipt of a National Institute of Health (NIH) Small Business Innovative Research (SBIR) grant for detecting gluten in food.

Key Points: 
  • A rapid, field-portable consumer sensor for detecting gluten in food.
  • MADISON, Wis., Aug. 7, 2023 /PRNewswire-PRWeb/ -- Amulet , maker of the world's smallest, fastest, and portable electrochemical food sensor, announced today the receipt of a National Institute of Health (NIH) Small Business Innovative Research (SBIR) grant for detecting gluten in food.
  • They include wheat allergy, gluten ataxia, dermatitis herpetiformis, non-celiac gluten sensitivity and celiac disease—an autoimmune disease in which the immune system reactions abnormally to gluten, causing damage to the lining of the small intestine.
  • Our goal at Amulet is to provide consumers with a tool to help them avoid gluten, and in turn, better manage their health," says Amulet Co-Founder & CEO, Abigail Barnes.

INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure

Retrieved on: 
Monday, June 5, 2023
Biotechnology, FDA, Health, Pharmaceutical, Cardiology, Heart failure, Palpitations, Hypophosphatemia, Heart, Classification, Fatigue, Hypertension, New York Heart Association Functional Classification, Iron deficiency, Patient, Iron, Daiichi Sankyo, Anemia, Nausea, Periodic breathing, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPH, III, Food, Safety, Conditional sentence, Pharmaceutical industry, Dietary supplement, MD

Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.1

Key Points: 
  • Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration (FDA) approved INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III to improve exercise capacity.1
    “This new indication for INJECTAFER marks the first and only FDA approval of an intravenous iron replacement therapy for adult patients with heart failure, a progressive and chronic disease.
  • Approximately 2.8 million U.S. adults are impacted by heart failure with iron deficiency or iron deficiency anemia, which can affect their daily lives and activities,”1-10 said Ravi Tayi, MD, MPH, Chief Medical Officer at American Regent, Inc. “INJECTAFER is the most extensively studied intravenous iron and this latest approval continues to build on the effective and proven use of INJECTAFER for adult and pediatric patients with iron deficiency anemia, and now for adult patients with heart failure who have iron deficiency.”11
    The New York Heart Association Functional Classification classifies patients’ heart failure based on the severity of their symptoms.
  • Patients who have a slight or marked limitation of their physical activity due to fatigue, palpitation and/or dyspnea are considered to have class II or class III heart failure, respectively.12
    The approval was supported by INJECTAFER data from a randomized controlled study, CONFIRM-HF (NCT01453608), that evaluated the efficacy and safety of INJECTAFER in adult patients with chronic heart failure and iron deficiency.
  • Treatment with INJECTAFER significantly improved exercise capacity compared to placebo in iron deficient patients with heart failure.13 The safety results from the trial were generally consistent with the known safety profile of INJECTAFER.

Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure

Retrieved on: 
Monday, June 5, 2023
Exercise, ST, Heart failure, Palpitations, American Heart Association, Health care, Heart, European Society of Cardiology, American College of Cardiology, CSL, CSL Vifor, Classification, Heart Failure Society of America, Fatigue, New York Heart Association Functional Classification, Iron deficiency, Patient, Health professional, Periodic breathing, American College, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I.V. (song), III, Food, Safety, Dietary supplement, Pharmaceutical industry, Cardiology

ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer® for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.1  

Key Points: 
  • "Every second patient with chronic heart failure suffers from iron deficiency, with a significant number of patients either not being diagnosed or inadequately treated for iron deficiency.
  • We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients."
  • The value of treating iron deficiency in heart failure patients has been clearly recognized by leading guideline committees such as the American Heart Association, the American College of Cardiology, the Heart Failure Society of America as well as the European Society of Cardiology.
  • *The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients' heart failure based on the severity of their symptoms.

Injectafer® approved in the U.S. for the treatment of iron deficiency in patients with heart failure

Retrieved on: 
Monday, June 5, 2023
Exercise, ST, Heart failure, Palpitations, American Heart Association, Health care, Heart, European Society of Cardiology, American College of Cardiology, CSL, CSL Vifor, Classification, Heart Failure Society of America, Fatigue, New York Heart Association Functional Classification, Iron deficiency, Patient, Health professional, Periodic breathing, American College, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I.V. (song), III, Food, Safety, Dietary supplement, Pharmaceutical industry, Cardiology

ST. GALLEN, Switzerland, June 5, 2023 /PRNewswire/ -- CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its partner American Regent, Inc., a Daiichi Sankyo Group company, approval for Injectafer® for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.1  

Key Points: 
  • "Every second patient with chronic heart failure suffers from iron deficiency, with a significant number of patients either not being diagnosed or inadequately treated for iron deficiency.
  • We are confident that Injectafer® can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients."
  • The value of treating iron deficiency in heart failure patients has been clearly recognized by leading guideline committees such as the American Heart Association, the American College of Cardiology, the Heart Failure Society of America as well as the European Society of Cardiology.
  • *The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients' heart failure based on the severity of their symptoms.

Scientific Statement on Diagnosis and Treatment of Iron Deficiency in Heart Failure Released by Heart Failure Society of America

Retrieved on: 
Monday, May 1, 2023
Doctor of Pharmacy, Heart failure, Prevalence, Hospital, Heart Failure Society of America, Research, Journal of Cardiac Failure, Journal, Iron deficiency, MD, Patient, Risk, Diagnosis, Mortality, Knowledge, Dietary supplement, HF

ROCKVILLE, Md., May 1, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA) today released a new scientific statement on iron deficiency in heart failure (HF).

Key Points: 
  • ROCKVILLE, Md., May 1, 2023 /PRNewswire/ -- The Heart Failure Society of America (HFSA) today released a new scientific statement on iron deficiency in heart failure (HF).
  • The HFSA scientific statement provides valuable information on the diagnosis and treatment of iron deficiency in HF.
  • The paper discusses why iron deficiency commonly arises in HF, how iron deficiency should be evaluated, and the wide array of iron formulations currently available.
  • The Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of America will be published in the Journal of Cardiac Failure and available online at www.onlinejcf.com .